Ipsen to acquire all outstanding shares of Epizyme at $1.45/share for an initial consideration of ~$247M along with 1 CVR/share representing a premium of ~144% at Epizyme’s closing price of $0.60 over 30 days. The transaction is expected to close at the end of Q3’22
The holder of each CVR will receive $0.30/CVR upon reaching $250M in net sales of Tazverik (Ex-Japan & Greater China) by Dec 2026 & $0.70/CVR upon US approval for Tazverik & R2 in FL by Jan 2028
The acquisition combines Ipsen’s capabilities & resources in oncology with Epizyme’s to bolster Tazverik’s growth (currently in the P-III (SYMPHONY-1) trial, results are expected in 2026) for FL. Ipsen will also acquire EZM0414 in P-I/Ib trial for r/r MM & DLBCL
Ref: Bussinesswire | Image: Ipsen
